Therefore, before they can be successfully applied in a clinical setting to patients, there may be several technical barriers that must be overcome to ensure that HIF-2α-targeting small molecules can be efficiently delivered to chondrosarcomas. Here, EPAS1 is linked to chondrosarcoma.